IFNG and non-small cell lung carcinoma: Twenty two HLA-A2+ patients who had inoperable (stage IIIb or IV) NSCLC with neutrophils ≥ 1.5 × 109/L and showed immune responses or disease stabilization following four rounds of a first-line platinum-based chemotherapy were qualified for receiving IFNγ dexosome [163].